Your browser doesn't support javascript.
loading
Top advances in lung cancer, 2021.
Mohindra, Nisha A; Patel, Jyoti D.
Afiliación
  • Mohindra NA; Division of Hematology and Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
  • Patel JD; Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, USA.
Cancer ; 128(19): 3434-3437, 2022 10 01.
Article en En | MEDLINE | ID: mdl-35947027
Despite a global pandemic that continued to inflict chaos and confusion on the world, resulting in fewer cancer screenings and delayed surgeries, remarkable lung cancer treatment advancements were made in 2021. From immunotherapy in the adjuvant setting to the approval of the first-in-class, highly selective inhibitor of KRAS G12C, these treatment advances have significant clinical impact in patients with lung cancer. LAY SUMMARY: There has been tremendous innovation in the treatment of nonsmall cell lung cancer. The year 2021 was marked by new approaches to adjuvant therapy and the availability of agents to target new subsets of nonsmall cell lung cancer.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Carcinoma de Pulmón de Células no Pequeñas / Neoplasias Pulmonares Límite: Humans Idioma: En Revista: Cancer Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Carcinoma de Pulmón de Células no Pequeñas / Neoplasias Pulmonares Límite: Humans Idioma: En Revista: Cancer Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos